EP 3621599 A2 20200318 - SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN ETEXILATE
Title (en)
SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN ETEXILATE
Title (de)
FESTE ORALE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON DABIGATRANETEXILAT
Title (fr)
COMPOSITIONS PHARMACEUTIQUES ORALES SOLIDES D'ÉTÉXILATE DE DABIGATRAN
Publication
Application
Priority
- TR 201706848 A 20170510
- TR 2018050220 W 20180510
Abstract (en)
[origin: WO2019004979A2] The present invention relates to solid oral pharmaceutical compositions, comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof.
IPC 8 full level
A61K 9/48 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61K 31/4439 (2006.01)
CPC (source: EA EP)
A61K 9/1611 (2013.01 - EA EP); A61K 9/1652 (2013.01 - EA EP); A61K 9/4808 (2013.01 - EP); A61K 9/4858 (2013.01 - EA EP); A61K 9/5015 (2013.01 - EA EP); A61K 9/5031 (2013.01 - EA EP); A61K 9/5047 (2013.01 - EA EP); A61K 9/5084 (2013.01 - EP); A61K 31/4439 (2013.01 - EA EP)
Citation (search report)
See references of WO 2019004979A2
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2019004979 A2 20190103; WO 2019004979 A3 20190411; AU 2018293361 A1 20200102; AU 2018293361 B2 20210916; BR 112019023781 A2 20200602; CO 2019013649 A2 20200515; EA 201992644 A1 20200407; EP 3621599 A2 20200318; EP 3634388 A2 20200415; NZ 759901 A 20211224; TR 201706848 A2 20181121; TR 201806309 A2 20181121
DOCDB simple family (application)
TR 2018050220 W 20180510; AU 2018293361 A 20180510; BR 112019023781 A 20180510; CO 2019013649 A 20191203; EA 201992644 A 20180510; EP 18811674 A 20180510; EP 18811675 A 20180510; NZ 75990118 A 20180510; TR 201706848 A 20170510; TR 201806309 A 20180504